Bita Fakhri

15PUBLICATIONS
83CO-AUTHORS
Molecular targetsHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Medical and biological physics not elsewhere classifiedPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Jan 26, 2026
Oncogenic SF3B1 mutations alter the splicing of mRNA noncoding regions to induce a novel therapeutic vulnerability.

Michal Sekrecki, Agata Sekrecka, Rohan R Lattupally

|Jan 16, 2026
Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R marginal zone lymphoma: phase 1/2 BRUIN study.

Krish Patel, Julie M Vose, Sunita D Nasta

|Aug 22, 2025
Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R follicular lymphoma: phase 1/2 BRUIN study.

Nirav N Shah, Pier Luigi Zinzani, Michael Wang

|Jul 25, 2024
Real-world comparative effectiveness of venetoclax-obinutuzumab versus Bruton tyrosine kinase inhibitors for frontline chronic lymphocytic leukaemia.

Nilanjan Ghosh, Beenish S Manzoor, Bita Fakhri

|Apr 16, 2024
Real-World Health Care Resource Use and Costs Among Patients With Chronic Lymphocytic Leukemia Treated With Venetoclax-Based and Bruton Tyrosine Kinase Inhibitor-Based Regimens in the Second-Line Setting.

Bita Fakhri, Nnadozie Emechebe, Beenish S Manzoor

|Feb 05, 2024
Hypertension treatment for patients receiving ibrutinib: a multicenter retrospective study.

Laura Samples, Jenna Voutsinas, Bita Fakhri

Pageof 3

Frequent Collaborators

3 joint publications

Jonathon B Cohen

3 joint publications

John N Allan

2 joint publications

Jennifer Woyach

2 joint publications

Chaitra Ujjani